Bristol Myers Squibb (BMY)
(Real Time Quote from BATS)
$42.08 USD
-0.59 (-1.38%)
Updated Jul 23, 2024 12:10 PM ET
3-Hold of 5 3
B Value B Growth F Momentum B VGM
Price, Consensus and EPS Surprise
BMY 42.08 -0.59(-1.38%)
Will BMY be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BMY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BMY
Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Q2 Release
BMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
EMA Begins Review of Bristol Myers' (BMY) Opdivo Plus Yervoy for HCC
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for
Bristol Myers Squibb (BMY) Declines More Than Market: Some Information for Investors
Other News for BMY
UK dividends calendar - next 7 days
UK dividends calendar
Microsoft To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Monday
Hold Rating on Bristol-Myers Squibb Amid Mixed Performance and Evolving Pipeline
Bristol Myers price target lowered by $8 at Deutsche Bank, here's why